Beam Therapeutics Inc BEAM

$24.60 -0.17 (-0.69%)

Valuation

Market cap
2,558,444,000
Revenue TTM
$139,740,000
Net income TTM
$-79,990,000
PE ratio
0.00
Forward PE
—
Profit margin
-57.24%
Debt to equity
0.09

Trading

Volume
2,426,100
Avg volume
1,815,298
Day's range
$23.91 – $24.69
Shares out
103,288,000
Stochastic %K
33%
Beta
2.20
Analysts
Strong Sell
Price target
$48.43

Price

Company profile

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparti...

Show more

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a. The company also develops the ESCAPE platform, which combines antibody-based conditioning with multiplex gene edited HSCs. In addition, it develops BEAM-103, an anti-CD117 monoclonal antibody that enables ESCAPE. The company has research collaboration agreement with Pfizer Inc., focusing on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Verve Therapeutics, Inc., for cardiovascular disease treatments; and Orbital Therapeutics to design RNA for the prevention, treatment, or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Phone
857 327 8775
Website
https://beamtx.com
Address
238 Main Street, Cambridge, United States

Latest news

Stocktwits

DOGBIRD Oct 7, 12:37 AM
$PRME $BEAM if David wins nobel, wonder how these 2 will react.
0 replies
Merlintrader Oct 5, 9:37 AM
Beam Therapeutics ($BEAM): BEAM-302 ERS Evidence and the Risto-cel Year-End Filing Watch Explore the company, catalysts and risks in our research hub. https://www.merlintrader.com/beam-therapeutics-stock-hub/
0 replies
Gemology Oct 2, 12:55 PM
$BEAM The pressure will reveal what this is made of
0 replies
IR_propancbiopharma Oct 1, 7:36 PM
PRP’s path to the clinic is no longer just a development plan. The infrastructure behind it is taking shape. $PPCB has established key relationships supporting Phase 1b, including Avance Clinical for clinical delivery, a specialized CDMO for GMP manufacturing, and FyoniBio for PRP’s PK assay. Clinical development requires multiple pieces to come together. For PRP, those pieces are now being put in place. The foundation for the next stage is being built now. $IONS $BEAM
1 replies
Juhanialainen Oct 1, 9:22 AM
$BEAM Everything you need for tracking biotech catalysts, PDUFA dates, dilution, cash, social sentiment, price alerts etc: https://bioradar.io
0 replies
oz101 Oct 1, 3:49 AM
$CRSP $NTLA $BEAM $EDIT These stocks will have their day in the sun too so we should be grateful theyre trading so low. Just about every other mfer in the $XBI is killing it or had its chance. These will too.
0 replies
LookNoHands Sep 30, 9:08 PM
$BEAM 🚨 Meaningful BEAM development today, September 30: Beam Therapeutics⁠ has filed a lawsuit alleging that former Beam scientist Zi Jun “Emma” Wang misappropriated confidential base-editing technology and used it to help create YolTech Therapeutics. The dispute is particularly relevant because YolTech's YOLT-202/SERP-01 targets AATD—the same disease as BEAM-302—and uses base editing. Beam alleges Wang secretly co-founded YolTech while still employed at Beam and that the competing AATD program was developed using Beam trade secrets. The commercial stakes are potentially substantial: YolTech recently licensed SERP-01 outside Greater China to Serapha Bio in a deal containing more than 2 billion dollars in potential milestones, and Serapha is also named in Beam's lawsuit. Serapha denies the allegations.
0 replies
AdmiralTweezers Sep 29, 11:58 PM
$EDIT $NTLA $CRSP $BEAM Any stock with over 10 DTC (days to cover) is a short squeeze candidate. Right now NTLA is the easiest to envision squeezing especially if they announce completion of enrollment into Magnitude-2. Is anyone else out there tracking this? The FDA said no advisory committee--which means the 6 month timeline is shorted by MONTHS bc a PDUFA holds advisory 2 months before the PDUFA. I think this stock is going to pop on a catalyst. But wait, there's more! FDA gave Lonvo-Z RMAT designation. It allowed a rolling BLA. IntelliJ participated in FDA"s CMC Dev and Readiness Pilot. Then the FDA granted priority review. I'm expanding my investment here.
1 replies